Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma Journal Article


Authors: Romaguera, J. E.; Wang, M.; Feng, L.; Fayad, L. E.; Hagemeister, F.; McLaughlin, P.; Rodriguez, M. A.; Fanale, M.; Orlowski, R.; Kwak, L. W.; Neelapu, S.; Oki, Y.; Pro, B.; Younes, A.; Samaniego, F.; Fowler, N.; Hartig, K.; Valentinetti, M.; Smith, J.; Ford, P.; Naig, A.; Medeiros, L. J.; Kantarjian, H. M.; Goy, A.
Article Title: Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
Abstract: BACKGROUND: Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials with known effective agents. METHODS: This is a report of a prospective phase 2 trial of bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-hyperCVAD)/rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) for 95 patients with newly diagnosed MCL. RESULTS: The overall and complete response rates were 100% and 82%, respectively. Hematologic toxicity was high but expected and did not lead to an increased incidence of neutropenic fever or dose reductions in comparison with a similar reported regimen without bortezomib. After a median follow-up of 44 months, the median overall survival had not been reached, and the time to treatment failure (TTF) was 55 months, which is not different from that of historical controls. CONCLUSIONS: BzR-hyperCVAD/BzR-MA at the dose and schedule studied produced high rates of response and a TTF similar to that of historical reports without bortezomib. Cancer 2018;124:2561-9. © 2018 American Cancer Society. © 2018 American Cancer Society
Keywords: doxorubicin; bortezomib; mantle cell lymphoma; vincristine; and dexamethasone (r-hypercvad); rituximab plus hyperfractionated cyclophosphamide
Journal Title: Cancer
Volume: 124
Issue: 12
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2018-06-15
Start Page: 2561
End Page: 2569
Language: English
DOI: 10.1002/cncr.31361
PROVIDER: scopus
PUBMED: 29723393
DOI/URL:
Notes: Article -- Export Date: 2 July 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Anas Younes
    187 Younes